In May 2022 the Anti-Doping Agency of Kenya (ADAK) reported an anti-doping rule violation against the Athlete Keli Everlyne Syombua after her sample tested positive for the prohibited substance 19-norandrosterone and 19-noretiocholanolone (Nandrolone).
Following notification a provisional suspension was ordered. The Athlete filed a statement in her defence and the case was referred to the Kenya Sports Disputes Tribunal.
The Athlete admitted the violation and denied the intentional use of the substance. She explained with medical information that the prescribed substance substance was used in a hospital as treatment for her knee injury.
ADAK contended that the Athlete failed to demonstrate that the violation was not intentional, nor how the substance had entered her system. Furthermore ADAK's investigation had established that the medical evidence produced by the Athlete were falsifications.
The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that she committed an anti-doping rule violation.
The Panel determines that the Athlete failed to establish that the violation was not intentional, nor how the substance had entered her system. The Panel deems that the Athlete clearly acted intentionally regarding the falsified medical information.
Therefore the Panel decides on 16 February 2023 to impose a 4 year period of ineligibility on the Athlete, starting on 12 June 2022.
